It started in 2020 and had been due to follow up patients ... front among developers of Tim3-targeted drugs, slightly ahead of GSK and partner AnaptysBio with cobolimab, which is being tested ...

Booz Allen Hamilton, Guidehouse and others are negotiating with the General Services Administration as part of a broad review ...

Hundreds of protests at Tesla showrooms have also weighed on the company. Under the banner of a “Tesla Takedown,” opponents ...

With a lack of real breakthroughs since the 1960s, older methods such as electrical-based therapies are experiencing a revival in psychiatry.

The first patient has been treated with an implantable bioelectronic device developed by Galvani Therapeutics, set up by GlaxoSmithKline ... up to $429 million in 2020, taking control of its ...

(2020) Ferroptosis occurs through an osmotic mechanism and propagates independently of cell rupture. Nat Cell Biol. Sep 22; (9):1042-1048. Katikaneni A, Jelcic M, Gerlach GF, Ma Y, Overholtzer M, ...

Non-retail Specialty Drugs Market forecast to 2035 highlights market size and key therapeutic trends. It focuses on growing demand for complex therapies through specialized healthcare channels.

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, ...

Will Pahalgam attack impact stock markets? Volatility gauge sees biggest intraday jump since Apr 7 ...